Navigation Links
Experimental Cancer Vaccines Show Promise
Date:4/15/2008

They target malignancies of the cervix, prostate and breast, among others

TUESDAY, April 15 (HealthDay News) -- A germ that commonly causes food poisoning may be the next weapon in the fight against cervical cancer, a major cause of death among women worldwide.

A new trial shows that a live Listeria vaccine called Lovaxin C is safe and even showed some benefit in 15 women with advanced cervical cancer.

Listeria is a common bacteria found on leafy vegetables and dairy products. "Most of us eat it routinely but don't know it, because it generates a strong immune reaction," study lead author John Rothman, vice president of clinical development at Advaxis Inc. of North Brunswick, N.J., which makes the vaccine, said at a Tuesday news conference. "It can cause disease, but it's safe, because the lowest doses of any number of antibiotics will clear it and will do it without impeding the immune response."

This vigorous immune response is what researchers are hoping will give the vaccine a fighting chance against cervical cancer. According to Rothman, there are at least 10 ways that Listeria attacks tumors, and probably more.

Most of the women involved in this study had stage 4 disease and had failed prior surgery, chemotherapy or radiation. All women were given the vaccine as well as the antibiotic ampicillin.

By study's end, only five patients still had progressive disease, seven were stable and one demonstrated a partial response to the vaccine. Three of the seven stable patients showed tumor reductions of about 20 percent and one of more than 30 percent.

The vaccine did cause flu-like symptoms in all patients (fever, chills, nausea), but those who had received lower-dose vaccines were treated easily with over-the-counter drugs, the researchers said.

Rothman's study was just one of several showing promise that were presented Tuesday at the American Association for Cancer Research annual meeting, in San Diego.

A second study, out of the Netherlands, found that the GVAX vaccine stimulated a significant immune response in men with prostate cancer. Five out of six participants receiving the highest dose of vaccine showed declines in PSA (prostate-specific antigen) levels of 50 percent or more.

"This appears to be a promising approach," study lead author Saskia Santegoets of VU University Medical Center in Amsterdam, said at the news conference.

Another vaccine -- this one for prostate cancer that hasn't responded to other therapies -- also showed hope. Three of six patients who received the highest dose of the vaccine saw declines in PSA levels of more than 50 percent. The trial involved 24 patients overall.

According to lead author Dr. Lawrence Fong of the University of California, San Francisco, the vaccine works by "educating" the immune system."

And, finally, antibody directed enzyme pro-drug therapy (ADEPT) showed positive responses in 44 percent of patients with either colorectal, gastro-esophageal, breast, gallbladder, peritoneal, appendix, pancreas or cancer of unknown primary site. With ADEPT, an enzyme activates a drug that has been targeted to the tumor by an antibody, at the site of the tumor.

More information

The U.S. National Cancer Institute has more on cancer vaccines.



SOURCES: April 15, 2008, teleconference with John Rothman, Ph.D., vice president of clinical development, Advaxis Inc., North Brunswick, N.J.: Saskia Santegoets, VU University Medical Center, Amsterdam, the Netherlands; Lawrence Fong, M.D., University of California, San Francisco; American Association for Cancer Research annual meeting, San Diego


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Cancer Vaccines Show Promise
(Date:8/19/2017)... ... August 19, 2017 , ... Yesterday, the President of the United States ... two sides. There are not two sides to hatred, bigotry, discrimination, and a white ... and the NPEIV stands against all forms of such hatred and discrimination in this ...
(Date:8/18/2017)... ... August 19, 2017 , ... Mr. ... presided over the Amazing Thailand Health and Wellness Tourism Showcase 2017 yesterday, which ... Pakprot, Deputy Governor for Tourism Products and Business at TAT said, “Thailand has ...
(Date:8/18/2017)... York, NY (PRWEB) , ... August 18, 2017 ... ... edition of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting ... resources available for individuals with hearing impairments and shares the latest innovations in ...
(Date:8/18/2017)... , ... August 18, 2017 , ... The Dawn Johnson ... inaugurating a new charity drive to generate community support for efforts to educate the ... cures and treatments for all types of cancer. , Each day in America, ...
(Date:8/18/2017)... ... 2017 , ... MLM Insurance Group, a Miami area provider ... is working to support the Take Stock In Children Foundation during a regional ... The Take Stock In Children Foundation (TSC) offers guidance and assistance to low ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Inc. announced today that its fully owned USA ... York City Office in Yonkers, New York ... (TWO 2 ) homecare therapy. This new East Coast location has ... under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New ...
(Date:8/8/2017)... --   Second-quarter 2017 revenues ... per share from continuing operations ... percent to $110 million ... $161 million Second-quarter 2017 ... increased 8 percent to $0.93 ...
(Date:8/7/2017)... DUBLIN , Aug. 7, 2017  Endo International ... has reached agreements to resolve virtually all known U.S. ... in discussions to resolve the known remaining U.S. claims ... installment payments beginning in the fourth quarter of 2017 ... part of its second quarter 2017 results, the Company ...
Breaking Medicine Technology: